Taking a closer look at the design of the 58-subject study, half received Enhertu solo, while another 29 were given Enhertu plus the hormone treatment anastrozole. Patients were further broken ...

TOKYO & BASKING RIDGE, N.J., May 07, 2025--(BUSINESS WIRE)--Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings ...

The FDA has said AstraZeneca and Daiichi Sankyo’s Enhertu could be a breakthrough in a potential new lung cancer niche, the second time in the space of a week that the drug has received ...

But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically significant and clinically meaningful improvement in progression-free ...

(RTTNews) - The U.S. Food and Drug Administration approved AstraZeneca (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients ...